Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy

Cell Mol Immunol. 2024 May;21(5):436-447. doi: 10.1038/s41423-024-01153-x. Epub 2024 Apr 11.

Abstract

Immunotherapy has shown robust efficacy in treating a broad spectrum of hematological and solid cancers. Despite the transformative impact of immunotherapy on cancer treatment, several outstanding challenges remain. These challenges include on-target off-tumor toxicity, systemic toxicity, and the complexity of achieving potent and sustainable therapeutic efficacy. Synthetic biology has emerged as a promising approach to overcome these obstacles, offering innovative tools for engineering living cells with customized functions. This review provides an overview of the current landscape and future prospects of cancer immunotherapy, particularly emphasizing the role of synthetic biology in augmenting its specificity, controllability, and efficacy. We delineate and discuss two principal synthetic biology strategies: those targeting tumor surface antigens with engineered immune cells and those detecting intratumoral disease signatures with engineered gene circuits. This review concludes with a forward-looking perspective on the enduring challenges in cancer immunotherapy and the potential breakthroughs that synthetic biology may contribute to the field.

Keywords: Adoptive cell therapy.; Cancer immunotherapy; Gene circuit; Gene therapy; Synthetic biology.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antigens, Neoplasm / immunology
  • Genetic Engineering
  • Humans
  • Immunotherapy* / methods
  • Neoplasms* / immunology
  • Neoplasms* / therapy
  • Synthetic Biology* / methods

Substances

  • Antigens, Neoplasm